BioPharmSignal logoBioPharmSignal

Biotech News

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

ProKidney (PROK)ProKidneyClinical readout

In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progression Bilateral kidney injection with rilparencel resulted in a 4.6 mL/min/1.73m 2 (78%) improvement in the annual

Related news

PROKProKidney2025-07-15 11:30 EST

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

PROKProKidney2026-03-18 20:00 EST

ProKidney Reports Full Year 2025 Financial Results and Business Highlights

View all latest news

ProKidney

Regenerative Kidney Medicine ProKidney develops cell therapies intended to preserve kidney function and delay progression to kidney failure. Its work focuses on patients with advanced chronic kidney disease and type 2 diabetes who face a high risk of dialysis or transplantation. Rilparencel Rilparencel, also known as REACT, is a...

Recent company news

PROKProKidney2026-08-10 20:05 EST

ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights

PROKProKidney2026-06-02 12:00 EST

ProKidney Appoints Kenneth Locke as Chief Technical Officer

PROKProKidney2026-05-15 15:45 EST

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

PROKProKidney2026-03-25 20:01 EST

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

PROKProKidney2026-03-18 20:00 EST

ProKidney Reports Full Year 2025 Financial Results and Business Highlights

Stock data

Close
1.61 USD
Market cap
389.88M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States